- Home
- JCE vs TVRD Comparison
JCE vs TVRD Comparison
Compare JCE & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCE
- TVRD
- Stock Information
- Founded
- JCE 2007
- TVRD 2017
- Country
- JCE United States
- TVRD United States
- Employees
- JCE N/A
- TVRD N/A
- Industry
- JCE Trusts Except Educational Religious and Charitable
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- JCE Finance
- TVRD Health Care
- Exchange
- JCE Nasdaq
- TVRD Nasdaq
- Market Cap
- JCE 253.3M
- TVRD 246.5M
- IPO Year
- JCE N/A
- TVRD N/A
- Fundamental
- Price
- JCE $15.47
- TVRD $21.45
- Analyst Decision
- JCE
- TVRD Strong Buy
- Analyst Count
- JCE 0
- TVRD 3
- Target Price
- JCE N/A
- TVRD $60.67
- AVG Volume (30 Days)
- JCE 49.7K
- TVRD 98.3K
- Earning Date
- JCE 01-01-0001
- TVRD 08-21-2025
- Dividend Yield
- JCE 9.26%
- TVRD N/A
- EPS Growth
- JCE N/A
- TVRD N/A
- EPS
- JCE N/A
- TVRD N/A
- Revenue
- JCE N/A
- TVRD N/A
- Revenue This Year
- JCE N/A
- TVRD N/A
- Revenue Next Year
- JCE N/A
- TVRD N/A
- P/E Ratio
- JCE N/A
- TVRD N/A
- Revenue Growth
- JCE N/A
- TVRD N/A
- 52 Week Low
- JCE $11.64
- TVRD $8.13
- 52 Week High
- JCE $14.28
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- JCE 64.08
- TVRD N/A
- Support Level
- JCE $14.36
- TVRD N/A
- Resistance Level
- JCE $15.55
- TVRD N/A
- Average True Range (ATR)
- JCE 0.26
- TVRD 0.00
- MACD
- JCE 0.04
- TVRD 0.00
- Stochastic Oscillator
- JCE 93.28
- TVRD 0.00
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.